Background: Neuregulin 1 (NRG1) fusion proteins have recently been identified as oncogenic drivers in a number of different  cancers with high unmet medical need. We have recently reported promising responses in patients harboring NRG1 fusions treated with the bispecific antibody MCLA-128 (Schram 2019). The objective of this study was to quantitatively summarize the frequency of tumors harboring NRG1 fusions reported in the published literature.

Conclusions: NRG1 fusions are present across a wide range of different solid tumor types, with most common tumor types of NSCLC and PDAC. NRG1 fusion-driven cancers represent a potential tumor-agnostic therapeutic target. The advent of new treatment options and increased genomic testing will allow a more precise estimation of the frequency of NRG1 fusions in cancer.